KDOQI CLINICAL PRACTICE GUIDELINE FOR DIABETES AND CKD: 2012 UPDATE

被引：1063

作者：

Bilous, Rudolf W. ^{[1
,2
,3
,4
]}

Gonzalez-Campoy, J. Michael ^{[5
,6
]}

Fradkin, Judith E. ^{[7
,8
,9
]}

Mauer, Michael ^{[5
]}

Molitch, Mark E. ^{[10
,11
]}

Narva, Andrew S. ^{[12
]}

Nelson, Robert G. ^{[13
]}

Sharma, Kumar ^{[14
]}

Tuttle, Katherine R. ^{[15
,16
,17
,18
,19
]}

Rocco, Michael V. ^{[20
]}

Berns, Jeffrey S. ^{[21
,22
]}

Wilt, Timothy J. ^{[23
]}

Ishani, Areef ^{[24
]}

Rector, Thomas S. ^{[23
]}

Slinin, Yelena

Fitzgerald, Patrick ^{[25
]}

Carlyle, Maureen ^{[26
,27
]}

机构：

[1] Newcastle Univ, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England

[2] James Cook Univ Hosp, Middlesbrough, Cleveland, England

[3] NIH, Metab Med Unit, Bethesda, MD 20892 USA

[4] Univ Minnesota, JDRF, Minneapolis, MN 55455 USA

[5] Univ Minnesota, Sch Med, Minneapolis, MN 55455 USA

[6] NIDDK, Div Diabet Endocrinol & Metab Dis DEMD, NIH, Bethesda, MD 20892 USA

[7] Yale Univ, New Haven, CT 06520 USA

[8] Ctr Dis Control & Prevent, Natl Diabet Educ Program, Atlanta, GA USA

[9] Natl Naval Med Ctr, Bethesda, MD USA

[10] Northwestern Univ, Feinberg Sch Med, Div Endocrinol Metab & Mol Med, Evanston, IL 60208 USA

[11] Univ Calif Los Angeles, Harbor Gen Hosp, Los Angeles, CA 90024 USA

[12] NIDDK, Natl Kidney Dis Educ Program, Bethesda, MD 20892 USA

[13] NIDDK, Phoenix, AZ USA

[14] Univ Calif San Diego, Ctr Renal Translat Med, San Diego, CA 92103 USA

[15] Providence Sacred Heart Med Ctr, Spokane, WA USA

[16] Natl Diabet Educ Program NIH & CDC, Healthcare Profess Work Grp, Bethesda, MD 20892 USA

[17] Inst Review Board, Spokane, WA USA

[18] Univ Washington, Sch Med, Seattle, WA 98195 USA

[19] Washington State Univ, Pullman, WA 99164 USA

[20] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA

[21] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA

[22] Univ Penn, Sch Med, Penn Presbyterian Med Ctr Philadelphia, Philadelphia, PA 19104 USA

[23] Vet Affairs Med Ctr, Ctr Chron Dis Outcomes Res, Minneapolis, MN USA

[24] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA

[25] CCDOR, Minneapolis, MN USA

[26] Minneapolis VA Ctr Chron Dis Outcomes Res, Minneapolis, MN USA

[27] Univ Minnesota, Minnesota Evidence Based Practice Ctr, Minneapolis, MN 55455 USA

来源：

AMERICAN JOURNAL OF KIDNEY DISEASES | 2012年 / 60卷 / 05期

关键词：

Albuminuria; chronic kidney disease; Clinical Practice Guideline; diabetes; dyslipidemia; evidence-based recommendation; KDOQI; CONVERTING ENZYME-INHIBITION; CHRONIC KIDNEY-DISEASE; ALBUMIN EXCRETION RATE; GLYCEMIC CONTROL; SEVERE HYPOGLYCEMIA; CARDIOVASCULAR EVENTS; RENAL IMPAIRMENT; MICROVASCULAR OUTCOMES; MYOCARDIAL-INFARCTION; SECONDARY PREVENTION;

D O I：

10.1053/j.ajkd.2012.07.005

中图分类号：

R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];

学科分类号：

1002 ; 100201 ;

摘要：

The 2012 update of the Kidney Disease Outcomes Quality Initiative (KDOQI) Clinical Practice Guideline for Diabetes and Chronic Kidney Disease (CKD) is intended to assist the practitioner caring for patients with diabetes and CKD. Substantial high-quality new evidence has emerged since the original 2007 KDOQI guideline that could significantly change recommendations for clinical practice. As such, revisions of prior guidelines are offered that specifically address hemoglobin A(1c) (HbA(1c)) targets, treatments to lower low-density lipoprotein cholesterol (LDL-C) levels, and use of angiotensin-converting enzyme inhibitor (ACE-I) and angiotensin receptor blocker (ARB) treatment in diabetic patients with and without albuminuria. Treatment approaches are addressed in each section and the stated guideline recommendations are based on systematic reviews of relevant trials. Appraisal of the quality of the evidence and the strength of recommendations followed the Grading of Recommendation Assessment, Development, and Evaluation (GRADE) approach. Limitations of the evidence are discussed and specific suggestions are provided for future research.

引用

页码：858 / +

页数：30

共 115 条

[51] Effect of renal impairment on the pharmacokinetics of the GLP-1 analogue liraglutide [J].

Jacobsen, Lisbeth V. ;

Hindsberger, Charlotte ;

Robson, Richard ;

Zdravkovic, Milan .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2009, 68 (06) :898-905

[52] Fluvastatin prevents cardiac death and myocardial infarction in renal transplant recipients:: Post-hoc subgroup analyses of the ALERT study [J].

Jardine, AG ;

Holdaas, H ;

Fellström, B ;

Cole, E ;

Nyberg, G ;

Grönhagen-Riska, C ;

Madsen, S ;

Neumayer, HH ;

Maes, B ;

Ambühl, P ;

Olsson, AG ;

Holme, I ;

Fauchald, P ;

Gimpelwicz, C ;

Pedersen, TR .

AMERICAN JOURNAL OF TRANSPLANTATION, 2004, 4 (06) :988-995

[53] Exenatide may aggravate moderate diabetic renal impairment: a case report [J].

Johansen, Odd Erik ;

Whitfield, Rolf .

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2008, 66 (04) :568-569

[54] Pharmacokinetics of glibenclamide and its metabolites in diabetic patients with impaired renal function [J].

Jönsson, A ;

Rydberg, T ;

Sterner, G ;

Melander, A .

EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1998, 53 (06) :429-435

[55] Long-term glycemic control measurements in diabetic patients receiving hemodialysis [J].

Joy, MS ;

Cefalu, T ;

Hogan, SL ;

Nachman, PH .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2002, 39 (02) :297-307

[56] A1C and survival in maintenance hemodialysis patients [J].

Kalantar-Zadeh, Kamyar ;

Aronovitz, Jason ;

Kopple, Joel D. ;

McAllister, Charles J. ;

Regidor, Deborah L. ;

Whellan, David ;

Jing, Jennie ;

Sharma, Kumar ;

Shinaberger, Christian S. .

DIABETES CARE, 2007, 30 (05) :1049-1055

[57] Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study):: randomised controlled trial [J].

Keech, A ;

Simes, RJ ;

Barter, P ;

Best, J ;

Scott, R ;

Taskinen, MR ;

Forder, P ;

Pillai, A ;

Davis, T ;

Glasziou, P ;

Drury, P ;

Kesäniemi, YA ;

Sullivan, D ;

Hunt, D ;

Colman, P ;

d'Emden, M ;

Whiting, M ;

Ehnholm, C ;

Laakso, M .

LANCET, 2005, 366 (9500) :1849-1861

[58] The 10-year incidence of renal insufficiency in people with type 1 diabetes [J].

Klein, R ;

Klein, BEK ;

Moss, SE ;

Cruickshanks, KJ ;

Brazy, PC .

DIABETES CARE, 1999, 22 (05) :743-751

[59] Meta-analysis: Effect of monotherapy and combination therapy with inhibitors of the renin-angiotensin system on proteinuria in renal disease [J].

Kunz, Regina ;

Friedrich, Chris ;

Wolbers, Marcel ;

Mann, Johannes F. E. .

ANNALS OF INTERNAL MEDICINE, 2008, 148 (01) :30-48

[60] Proteinuria as a Surrogate Outcome in CKD: Report of a Scientific Workshop Sponsored by the National Kidney Foundation and the US Food and Drug Administration [J].

Levey, Andrew S. ;

Cattran, Daniel ;

Friedman, Aaron ;

Miller, W. Greg ;

Sedor, John ;

Tuttle, Katherine ;

Kasiske, Bertram ;

Hostetter, Thomas .

AMERICAN JOURNAL OF KIDNEY DISEASES, 2009, 54 (02) :205-226

← 1 2 3 4 5 6 7 8 9 10 →